Puma Biotechnology (PBYI) Assets Average (2011 - 2026)

Puma Biotechnology has reported Assets Average for 16 years, with the latest figure at $204.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average changed 0.13% year-over-year to $204.5 million; the trailing twelve-month figure through Mar 2026 stood at $204.5 million (changed 0.13% YoY), and the FY2025 full-year result was $214.8 million, down 3.21% from the prior year.
• Assets Average for Q1 2026 stood at $204.5 million, down from $209.6 million in the prior quarter.
• The five-year high for Assets Average was $222.3 million in Q1 2024, with the low at $195.5 million in Q2 2025.
• Historically, Assets Average has averaged $207.0 million across 5 years, with a median of $209.2 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average slipped 23.97% — and 2024, when it advanced 6.3%.
• Puma Biotechnology's Assets Average stood at $210.4 million in 2022, then increased by 3.16% to $217.1 million in 2023, then retreated by 0.02% to $217.0 million in 2024, then dropped by 3.43% to $209.6 million in 2025, then fell by 2.42% to $204.5 million in 2026.
• The last three Assets Average figures came in at $204.5 million (Q1 2026), $209.6 million (Q4 2025), and $198.9 million (Q3 2025), per Business Quant data.